On August 11, 2021, the Northern District of Illinois in In re Opana ER Antitrust Litigation once again certified the classes of consumers and third-party payors (collectively known as “end payors”) that purchased or provided reimbursement for brand and generic versions of the pain-killing drug Opana ER.  The decision upholds a June class certification that was sent back for partial reconsideration. 

The plaintiffs allege that, as part of a patent settlement, Endo Pharmaceuticals, Inc. ("Endo") paid Impax Laboratories, Inc. ("Impax") millions of dollars to delay the launch of competing versions of the pain-killing drug Opana ER for over two years. 

Labaton Sucharow LLP serves as co-lead counsel for the end payor classes.

See In re Opana ER Antitrust Litigation for additional information on the case.